[ABT] Abbott Laboratories

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 38.41 Change: 0.12 (0.31%)
Ext. hours: Change: 0 (0%)

chart ABT

Refresh chart

Strongest Trends Summary For ABT

ABT is in the long-term up 65% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company?s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification,

Fundamental Ratios
Shares Outstanding EPS0.94 EPS Growth - 4 Quarters1349.62% EPS Growth - Q/Q238.84%
EPS Growth - Y/Y-44.39% Sales Growth - 4 Quarters -18.92% Sales Growth - Q/Q-7.43% P/E51.29
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA9.75% ROE19.21% ROI12.44%
Current Ratio2.17 Quick Ratio1.89 Long Term Debt/Equity0.55 Debt Ratio0.42
Gross Margin55.74% Operating Margin13.95% Net Profit Margin20.6% Dividend Payout Ratio-32.44%
Dividend Yield
Fundamental Data
Cash From Financing Activities-550 M Cash From Investing Activities-205 M Cash From Operating Activities2 M Gross Profit2.95 B
Net Profit784 M Operating Profit729 M Total Assets43.1 B Total Current Assets19.99 B
Total Current Liabilities9.21 B Total Debt8.46 B Total Liabilities21.22 B Total Revenue5.17 B
Technical Data
High 52 week63.54 Low 52 week44.97 Last close63.13 Last change-0.22%
RSI57.33 Average true range0.89 Beta0.56 Volume3.81 M
Simple moving average 20 days1.59% Simple moving average 50 days4.83% Simple moving average 200 days10.09%
Performance Data
Performance Week0.17% Performance Month4.24% Performance Quart-0.3% Performance Half15.98%
Performance Year35.54% Performance Year-to-date11.14% Volatility daily1.03% Volatility weekly2.3%
Volatility monthly4.71% Volatility yearly16.32% Relative Volume228.71% Average Volume5.71 M
New High New Low

News

2019-03-20 19:15:02 | Abbott Laboratories ABT Chairman and CEO Miles D White Sold $6 million of Shares

2019-03-20 14:27:06 | Abbott's ABT MitraClip COAPT Trial Shows Favorable Results revised

2019-03-20 11:05:03 | Medtronic MDT Releases Encouraging Evalut TAVR Result

2019-03-20 10:34:02 | Abbott ABT Gains Ground on Solid EPD and Diabetes Arms

2019-03-20 09:30:01 | Is Abbott Laboratories ABT Outperforming Other Medical Stocks This Year?

2019-03-20 09:00:00 | Abbott Hosts Conference Call for First-Quarter Earnings

2019-03-19 12:00:04 | What Makes Abbott ABT a New Buy Stock

2019-03-19 11:42:03 | Abbott's ABT MitraClip COAPT Trial Shows Favorable Results

2019-03-19 10:21:36 | Why You Should Buy ABBV Stock for Income and Value

2019-03-19 08:00:00 | Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

2019-03-19 07:00:00 | 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

2019-03-18 17:50:09 | Abbott ABT Stock Sinks As Market Gains: What You Should Know

2019-03-17 11:45:00 | New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump

2019-03-17 09:00:00 | New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device

2019-03-15 10:02:02 | Abbott ABT Gets FDA Approval for Expanded Use of MitraClip

2019-03-14 16:12:30 | Abbott Stock Isn't Heartbroken As FDA Approves New Valve Implant

2019-03-14 13:52:00 | Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device

2019-03-13 08:37:57 | FDA medical adviser: 'Congress is owned by pharma'

2019-03-12 17:50:09 | Abbott ABT Outpaces Stock Market Gains: What You Should Know

2019-03-12 10:25:40 | See what the IHS Markit Score report has to say about Abbott Laboratories.

2019-03-10 09:15:00 | Better Buy: Abbott Laboratories vs. Johnson & Johnson

2019-03-08 04:26:54 | [$$] Javid faces fresh row over Begum case after baby’s death

2019-03-06 09:11:02 | The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem

2019-03-06 09:00:00 | Late-Breaking Data Presentations at ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio

2019-03-05 13:32:06 | Top Analyst Reports for Boeing, Abbott & PayPal

2019-03-04 15:13:31 | Healthcare ETF Keeps Hitting New Highs

2019-03-04 08:31:01 | Here's Why You Should Snap Up Abbott ABT Stock Right Now

2019-03-04 06:40:11 | DENTSPLY's XRAY Preliminary Q4 Results Cheer Investors

2019-03-01 13:57:16 | What Wall Street Recommends for Amarin after Q4 2018 Results

2019-03-01 12:06:28 | Is Abbott Laboratories’s NYSE:ABT CEO Pay Justified?

2019-03-01 10:00:30 | Two under-the-radar health-care stocks are trading at record highs

2019-03-01 06:46:11 | Here's Why You Should Buy Varian Medical VAR Stock Now

2019-02-28 10:49:03 | Merit Medical MMSI Q4 Earnings & Revenues Surpass Estimates

2019-02-28 07:49:12 | Orthofix OFIX Earnings Beat Estimates in Q4, Margins Fall

2019-02-27 09:08:02 | Veeva Systems VEEV Beats on Q4 Earnings and Revenues

2019-02-27 08:19:01 | Wright Medical WMGI Q4 Earnings & Revenues Beat Estimates

2019-02-27 07:55:00 | Report: Developing Opportunities within Abbott Laboratories, American Express, Welbilt, Cinemark, Barnes Group, and Nevsun Resources — Future Expectations, Projections Moving into 2019

2019-02-26 18:04:11 | Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

2019-02-26 17:58:10 | Here's Why Investors Should Buy DexCom DXCM Stock Now

2019-02-26 16:30:16 | [$$] CEOs From Pfizer, Merck and Others Face Senate Over Drug Pricing

2019-02-26 10:41:03 | Teleflex TFX Q4 Earnings Miss Estimates, Margins Rise

2019-02-26 06:40:11 | Stryker Expands Acquisition Portfolio With Arrinex Buyout

2019-02-25 13:03:25 | Big Pharma to testify in Senate drug pricing hearing

2019-02-25 10:27:01 | See what the IHS Markit Score report has to say about Abbott Laboratories.

2019-02-25 09:00:00 | Abbott to Present at Barclays Global Healthcare Conference

2019-02-25 08:02:01 | CVS Health Rides on Aetna Synergy, PBM Selling Season Modest

2019-02-25 07:21:12 | Chemed CHE Q4 Earnings Beat Estimates, Gross Margin Falls

2019-02-22 16:48:36 | Abbott Laboratories ABT Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-22 12:49:05 | Abbott planning $62M expansion in Columbus, adding 38 jobs

2019-02-22 10:44:03 | Quest Diagnostics Grows on Innovation Amid Reimbursement Woe